- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04781140
취학전 ADHD 아동에서 SPN-812(Viloxazine Extended-release Capsule)의 평가
주의력 결핍/과잉 행동 장애(ADHD)가 있는 미취학 아동(4~5세)에서 SPN-812의 효능 및 안전성에 대한 4상, 무작위, 이중 맹검, 다기관, 위약 대조, 병렬 그룹 연구 )
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
연구 개요
상세 설명
This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel-group, efficacy and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with ADHD. Participants will be screened for eligibility for up to 4 weeks. Eligible participants will be treated with study medication for 6 weeks. The total duration of the study is up to 10 weeks.
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: Olivia Elbaum
- 전화번호: 301-838-2500
- 이메일: clinicaltrials@supernus.com
연구 장소
-
-
Alabama
-
Saraland, Alabama, 미국, 36571
- 모병
- The Center for Clinical Trials, Inc.
-
연락하다:
- 전화번호: 251-341-7021
- 이메일: info@thecenterforclinicaltrials.com
-
-
Arkansas
-
Fayetteville, Arkansas, 미국, 72703
- 빼는
- Preferred Research Partners-NWA, LLC
-
Little Rock, Arkansas, 미국, 72211
- 모병
- Preferred Research Partners, Inc.
-
연락하다:
- 전화번호: 501-553-9987
- 이메일: info@preferredresearchpartners.com
-
-
California
-
Anaheim, California, 미국, 92805
- 모병
- Advanced Research Center (ARC), Inc.
-
연락하다:
- 전화번호: 714-999-6688
- 이메일: contact@arctrials.com
-
Encino, California, 미국, 91316
- 빼는
- Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Encino]
-
Garden Grove, California, 미국, 92844
- 종료됨
- National Institute of Clinical Research (PICR)
-
Imperial, California, 미국, 92251
- 모병
- Sun Valley Research Center
-
연락하다:
- 전화번호: 760-545-0123
- 이메일: svrcinfo@sunvalleyb.com
-
Long Beach, California, 미국, 90807
- 모병
- Alliance Research
-
연락하다:
- 전화번호: 562-548-8500
- 이메일: Research@asclepes.com
-
Newport Beach, California, 미국, 92660
- 빼는
- Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Newport Beach]
-
-
Colorado
-
Centennial, Colorado, 미국, 80112
- 모병
- IMMUNOe Research Centers
-
연락하다:
- 전화번호: 303-771-9000
- 이메일: verosinfo@veroshealth.com
-
연락하다:
- 전화번호: 303-773-9000
-
-
Florida
-
Clermont, Florida, 미국, 34711
- 빼는
- Vertex Clinical Research, LLC
-
Coral Gables, Florida, 미국, 33134
- 모병
- Luna Research Center
-
연락하다:
- 전화번호: 305-613-7761
-
Gainesville, Florida, 미국, 32607
- 종료됨
- Sarkis Clinical Trials
-
Jacksonville, Florida, 미국, 32256
- 모병
- Clinical Neuroscience Solutions, Inc.
-
연락하다:
- 전화번호: 904-281-5757
-
Lakeland, Florida, 미국, 33803
- 종료됨
- Accel Research Sites - Lakeland CRU
-
Miami, Florida, 미국, 33155
- 모병
- Avantis Clinical Research LLC
-
연락하다:
- 전화번호: 305-515-9006
- 이메일: info@avantisclinicalresearch.com
-
Orange City, Florida, 미국, 32763
- 모병
- Medical Research Group of Central Florida
-
연락하다:
- 전화번호: 386-775-7627
-
Orlando, Florida, 미국, 32801
- 모병
- Clinical Neuroscience Solutions, Inc.
-
연락하다:
- 전화번호: 407-425-5100
- 이메일: orlinfo@cnshealthcare.com
-
Orlando, Florida, 미국, 32803
- 모병
- APG Research LLC
-
연락하다:
- 전화번호: 166 407-423-7149
- 이메일: kkenworthyapg@gmail.com
-
연락하다:
- 전화번호: 165 407-423-7149
-
Tamarac, Florida, 미국, 33321
- 모병
- D&H Tamarac Research Center
-
연락하다:
- 전화번호: 786-375-6210
- 이메일: info@dhnrc.com
-
Virginia Gardens, Florida, 미국, 33166
- 모병
- Hope Research Network, LLC.
-
연락하다:
- 전화번호: 786-953-8858
- 이메일: info@hoperesearchnetwork.com
-
Winter Park, Florida, 미국, 32789
- 모병
- Pediatric Neurology and Epilepsy Specialists
-
연락하다:
- 전화번호: 121 407-293-1122
- 이메일: ARiveraDelValle@pediatricneurologyandepilepsy.com
-
연락하다:
- 전화번호: 126 407-293-1122
- 이메일: DHubert@pediatricneurologyandepilepsy.com
-
-
Georgia
-
Atlanta, Georgia, 미국, 30328
- 모병
- Clinical Integrative Research Center of Atlanta
-
연락하다:
- 전화번호: 678-705-7341
-
Atlanta, Georgia, 미국, 30318
- 모병
- Advanced Discovery Research LLC
-
연락하다:
- 전화번호: 470-777-8839
- 이메일: contact@advdiscovery.com
-
Decatur, Georgia, 미국, 30030
- 모병
- CenExcel iResearch, LLC
-
연락하다:
- 전화번호: 404-537-1281
-
Savannah, Georgia, 미국, 31405
- 모병
- CenExel iResearch, LLC.
-
연락하다:
- 전화번호: 912-744-0800
-
-
Indiana
-
Evansville, Indiana, 미국, 47715
- 종료됨
- Qualmedica Research, LLC.
-
-
Kentucky
-
Bardstown, Kentucky, 미국, 40004
- 모병
- Kentucky Pediatric/Adult Research
-
연락하다:
- 전화번호: 502-349-1569
- 이메일: kpar@kpar.us
-
Owensboro, Kentucky, 미국, 42301
- 종료됨
- Qualmedica Research, LLC.
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70115
- 종료됨
- DelRicht Research (Touro Medical Center)
-
Prairieville, Louisiana, 미국, 70769
- 모병
- DelRicht Research
-
연락하다:
- 전화번호: 225-412-0316
- 이메일: info@delricht.com
-
-
Maryland
-
Baltimore, Maryland, 미국, 21205
- 모병
- Kennedy Krieger Institute
-
연락하다:
- 전화번호: 443-923-3850
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02445
- 모병
- Boston Children's Hospital
-
연락하다:
- 전화번호: 617-919-6954
-
연락하다:
- 전화번호: 617-355-1118
- 이메일: benamin.mills@childrens.harvard.edu
-
-
Michigan
-
Bloomfield Hills, Michigan, 미국, 48302
- 모병
- Neurobehavioral Medicine Group
-
연락하다:
- 전화번호: 248-290-5400
- 이메일: info@neurobmg.com
-
-
Mississippi
-
Flowood, Mississippi, 미국, 39232
- 모병
- Precise Research Centers
-
연락하다:
- 전화번호: 601-420-5812
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89128
- 모병
- Clinical Research of Southern Nevada, LLC.
-
연락하다:
- 전화번호: 702-750-0000
- 이메일: kluna.cpbm@gmail.com
-
-
New Jersey
-
Berlin, New Jersey, 미국, 08009
- 빼는
- Hassman Research Institute
-
Irvington, New Jersey, 미국, 07111
- 모병
- Med Clinical Research
-
연락하다:
- 전화번호: 908-798-8373
- 이메일: info@medclinicalresearch.com
-
Neptune City, New Jersey, 미국, 07753
- 모병
- Jersey Shore University Medical Center
-
연락하다:
- 전화번호: 732-897-3640
- 이메일: andrew.layman@hmhn.org
-
-
New York
-
New York, New York, 미국, 10028
- 빼는
- Icahn School of Medicine at Mount Sinai
-
-
North Carolina
-
Durham, North Carolina, 미국, 27705
- 모병
- Duke University
-
연락하다:
- 전화번호: 919-681-1100
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45229
- 모병
- Cincinnati Children's Hospital and Medical Center
-
연락하다:
- 전화번호: 513-636-9763
- 이메일: ADHDResearch@cchmc.org
-
West Chester, Ohio, 미국, 45069
- 빼는
- CincyScience
-
-
Oregon
-
Gresham, Oregon, 미국, 97030
- 모병
- Cyn3rgy Research
-
연락하다:
- 전화번호: 503-907-2179
- 이메일: support@cyn3rgy.com
-
-
Pennsylvania
-
Hershey, Pennsylvania, 미국, 17033
- 모병
- Penn State Health Medical Group - Psychiatry and Behavioral Health
-
연락하다:
- 전화번호: 287364 717-531-0003
- 이메일: rmyers12@pennstatehealth.psu.edu
-
연락하다:
- 전화번호: 717-531-5656
-
-
South Carolina
-
North Charleston, South Carolina, 미국, 29405
- 모병
- Coastal Carolina Research Center
-
연락하다:
- 전화번호: 843-856-3784
- 이메일: CCRC@CoastalCarolinaResearch.com
-
Summerville, South Carolina, 미국, 29486
- 모병
- Coastal Pediatric Research
-
연락하다:
- 전화번호: 843-870-2225
- 이메일: info.research@cpakids.com
-
-
Tennessee
-
Memphis, Tennessee, 미국, 38119
- 모병
- Clinical Neuroscience Solutions, Inc.
-
연락하다:
- 전화번호: 901-843-1045
-
-
Texas
-
Bellaire, Texas, 미국, 77401
- 빼는
- Houston Clinical Trials, LLC.
-
Dallas, Texas, 미국, 75230
- 종료됨
- Javara
-
Plano, Texas, 미국, 75093
- 모병
- AIM Trials, LLC
-
연락하다:
- 전화번호: 469-364-8804
- 이메일: info@aimtrials.com
-
연락하다:
- 전화번호: 214-856-2778
-
The Woodlands, Texas, 미국, 77381
- 모병
- Family Psych of The Woodlands
-
연락하다:
- 전화번호: 281-367-1015
- 이메일: info@woodlandspsych.com
-
-
Virginia
-
Petersburg, Virginia, 미국, 23805
- 모병
- Clinical Research Partners, LLC
-
연락하다:
- 전화번호: 804-921-9592
- 이메일: Recruitment@ClinicalResearchRVA.com
-
Richmond, Virginia, 미국, 23220
- 모병
- Virginia Commonwealth University, Virginia Treatment Center for Children
-
연락하다:
- 전화번호: 804-628-8736
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Is male or female 4 years 0 months of age to less than or equal to 5 years 9 months of age at Visit 1 (Screening) and considered medically healthy.
- Subject's parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent before completing any study related procedures.
- Has a primary diagnosis of ADHD according to DSM-IV-TR criteria and confirmed with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL).
- Has an ADHD-RS-IV-P Total Score of ≥ 28 (males) or ≥ 24 (females) at Visit 1 (Screening) and at Visit 2 (Baseline).
- Has a CGI-S score of ≥ 4 (moderate or worse) at Visit 1 (Screening) and at Visit 2 (Baseline).
- Has undergone an adequate course of non-pharmacologic treatment or is having symptoms severe enough to warrant pharmacologic treatment without prior non-pharmacologic treatment.
- Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school, summer camp or childcare program) at least 2 days a week during study so as to assess symptoms and impairment in a setting outside the home.
- Has not initiated any behavioral intervention/therapy within 30 days of Visit 1 (Screening) and does not plan to initiate any new or discontinue any ongoing behavioral intervention/therapy during the study (e.g., subject is eligible if behavioral intervention/therapy is initiated 30 or more days prior to Visit 1 [Screening] and continues with a similar duration/frequency throughout their study).
- Subjects who are on ADHD medication at Visit 1 (Screening), but whose ADHD symptoms are not well controlled on current ADHD medication (e.g., meets Inclusion Criterion #4), meet all other inclusion/exclusion criteria, and discontinues ADHD medication at least 7 days prior to the day of Visit 2 (Baseline) are eligible to participate.
- Has no current condition in the opinion of the Investigator that could confound efficacy assessments, safety assessments or increase participant risk.
- Has lived with the same parent(s) or legal guardian(s) or has lived under a shared living arrangement (e.g., joint legal custody) for greater than or equal to 6 months prior to Visit 1 (Screening).
- Has a body weight ≥5th percentile for age and sex at Visit 1 (Screening) and Visit 2 (Baseline).
Exclusion Criteria:
- Has a diagnosis at Screening (per K-SADS-PL) of another psychiatric disorder that is considered to be the primary diagnosis rather than ADHD or has a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator (after consulting medical monitor), will likely interfere with study treatment adherence and/or impact study results.
- Has a current diagnosis of a major neurological disorder. The eligibility of those who have seizures, a history of seizure-like events (e.g., syncope, myoclonus, severe muscle spasms), a family history of seizure disorder (immediate family, i.e., sibling, parent), and/or febrile seizures will be assessed on a case-by-case basis after consulting the medical monitor.
- History of Bipolar Disorder diagnosed in a first degree relative.
- Has global development delay or intellectual disability by medical history.
- Has a current diagnosis of a significant (per Investigator's evaluation and/or judgement) systemic disease.
- Has body mass index > 95th percentile for the subject's age and sex at Visit 1 (Screening) or Visit 2 (Baseline).
- Has a mean resting systolic and diastolic blood pressure* that are both >95th percentile for age sex, and height and has a mean resting pulse rate* that is >95th percentile for age and sex (males: >117 bpm; females: >122 bpm) at Visit 1 (Screening) or Visit 2 (Baseline). * Note: The mean of three measurements while seated.
- Has a clinically significant electrocardiogram finding(s) at Visit 1 (Screening).
- Is currently taking SPN-812 for ADHD, has previously taken SPN-812 for ADHD, but discontinued due to a lack of efficacy or adverse reactions, or has history of allergic reaction, hypersensitivity or intolerance to viloxazine.
- Has an allergy to or cannot swallow pudding and applesauce and cannot swallow intact capsule whole.
- Has any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in the study.
- Has received any investigational drug within the longer of 30 days or 5 half-lives prior to Visit 2 (e.g., first dose of study medication).
- Has a positive urine drug test at Visit 1 (Screening). A positive test for amphetamines is allowed for subjects receiving a stimulant ADHD medication at Screening. The subject will be required to discontinue the stimulant for the duration of the study, beginning at least 7 days prior to Visit 2 (Baseline).
- Is using of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) during the Screening Period or (anticipated) for the duration of the study.
- Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
- Has suicidal ideation ("Yes" indicated on C-SSRS question 4 or 5) or suicidal behavior ("Yes" indicated on C-SSRS for any suicidal behavior) within 6 months prior to or the day of Visit 1 (Screening) or has attempted suicide ("Yes" indicated on C-SSRS for lifetime).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: Placebo
Placebo, qd |
Placebo will be administered once daily |
|
실험적: SPN-812
SPN-812, qd |
100mg SPN-812 will be administered once daily and compared to Placebo
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Total Score at End of Study (Week 6)
기간: Baseline and Week 6
|
The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I", 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the ratings of all 18 items yields the raw Total score (range: 0-54; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline ADHD-RS-IV-P Total Score (<0) represents a better outcome. |
Baseline and Week 6
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score at End of Study (Week 6)
기간: Baseline and Week 6
|
The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients (the higher the score, the more severe the overall ADHD symptoms). Post-baseline (raw) CGI-S scores are converted to a change from baseline score. A lower change from baseline CGI-S score (<0) represents a better outcome. |
Baseline and Week 6
|
|
Clinical Global Impression of Change (CGI-C) Score at End of Study (Week 6)
기간: Week 6
|
The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". A CGI-C score <4 represents a better outcome. |
Week 6
|
|
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Hyperactivity/Impulsivity Subscale Score at End of Study (Week 6)
기간: Baseline and Week 6
|
The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine H/I items yields the raw H/I subscale score (range: 0-27; the higher the H/I subscale score, the more severe the H/I symptoms). Post-baseline raw H/I subscale scores are converted to a change from baseline score. A lower change from baseline H/I subscale score (<0) represents a better outcome. |
Baseline and Week 6
|
|
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Inattention Subscale Score at End of Study (Week 6)
기간: Baseline and Week 6
|
The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine IA items yields the raw IA subscale score (range: 0-27; the higher the IA subscale score, the more severe the IA symptoms). Post-baseline raw IA subscale scores are converted to a change from baseline score. A lower change from baseline IA subscale score (<0) represents a better outcome. |
Baseline and Week 6
|
|
Clinical Global Impression of Severity (CGI-S) Responder Rate (percentage of subjects with CGI-S score of 1 or 2) at End of Study (Week 6)
기간: Baseline and Week 6
|
The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients. The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders". |
Baseline and Week 6
|
|
Clinical Global Impression of Change (CGI-C) Responder Rate (percentage of subjects with CGI-C score of 1 or 2) at End of Study (Week 6)
기간: Week 6
|
The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders". |
Week 6
|
|
Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Responder Rate (percentage of subjects with ≥ 50% Reduction in Change from Baseline) at End of Study (Week 6)
기간: Baseline and Week 6
|
The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two 9 item subscales: inattention and hyperactivity-impulsivity. The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale; 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. Sum of 18 ratings yields the Total score (range: 0-54; higher score represents severer symptoms). Percent reduction is calculated for the ADHD-RS-IV-P score: [("Post-baseline"-"Baseline")/"Baseline"] x 100; range: 0 to 100%; a "responder" is a subject with a 50% or greater reduction in change from baseline Total score. Responder rate (percent of responders) is calculated: ["number of 'responders' (m)"/ "number of subjects analyzed" (n)] X 100; range: 0 to 100%. A Responder Rate greater than 50%, represents more "responders" versus "nonresponders". |
Baseline and Week 6
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Joseph Hull, PhD, Supernus Pharmaceuticals, Inc.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .